Next Article in Journal
Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development
Next Article in Special Issue
Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases
Previous Article in Journal
The Infantile Leukoencephalopathy-Associated Mutation of C11ORF73/HIKESHI Proteins Generates De Novo Interactive Activity with Filamin A, Inhibiting Oligodendroglial Cell Morphological Differentiation
Open AccessArticle

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease

1
Coral Ridge Medical Center, 821 Coral Ridge Drive, Coral Springs, FL 33065, USA
2
MD Stem Cells, 3 Sylvan Road South, Westport, CT 06880, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Tadayuki Akagi
Received: 22 December 2020 / Revised: 23 January 2021 / Accepted: 25 January 2021 / Published: 3 February 2021
Background: Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Methods: Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. The follow-up period was one year. Results: Of the 34 treated eyes, 21 (61.8%) improved, 8 (23.5%) remained stable, and 5 (14.7%) showed continued progression of their disease. Results were statistically significant with p = 0.0004. The average central vision improvement following treatment was 17.96% (95%CI, 16.39–19.53%) and ranged up to 80.5%. Of 17 patients treated, 13 (76.5%) showed visual acuity improvement in one or both eyes, 3 patients (17.6%) showed no net loss, and 1 worsened as a consequence of disease progression; 94.1% of patients had improved vision or remained stable. There were no adverse events. Conclusions: Patients with Stargardt Disease may potentially benefit from autologous bone marrow-derived stem cells (BMSC) as provided in SCOTS. Improvement or stabilization of vision was found to occur for the vast majority of reported patients and findings were highly statistically significant. View Full-Text
Keywords: Stargardt Disease; macular degeneration; SGDT1; bone marrow-derived stem cells; BMSC; stem cells; hereditary maculopathy; juvenile macular degeneration; hereditary macular degeneration; ABCA4 mutation Stargardt Disease; macular degeneration; SGDT1; bone marrow-derived stem cells; BMSC; stem cells; hereditary maculopathy; juvenile macular degeneration; hereditary macular degeneration; ABCA4 mutation
Show Figures

Graphical abstract

MDPI and ACS Style

Weiss, J.N.; Levy, S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease. Medicines 2021, 8, 10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010

AMA Style

Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease. Medicines. 2021; 8(2):10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010

Chicago/Turabian Style

Weiss, Jeffrey N.; Levy, Steven. 2021. "Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease" Medicines 8, no. 2: 10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop